Update on adjuvant hormonal treatment of early breast cancer

Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and overall survival. More recently, aromatase inhib...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2011-09, Vol.28 (Suppl 6), p.1-18
Main Authors: Lao Romera, Juan, Puertolas Hernández, Teresa de Jesús, Peláez Fernández, Ignacio, Sampedro Gimeno, Teresa, Fernández Martínez, Roberto, Fernández Pérez, Isaura, Iranzo González Cruz, Vega, Illarramendi Mañas, José Juan, Garcerá Juan, Salvador, Ciruelos Gil, Eva María
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - adverse effects
Aromatase Inhibitors - administration & dosage
Aromatase Inhibitors - adverse effects
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Cardiology
Chemotherapy, Adjuvant
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Endocrinology
Female
Follow-Up Studies
Health technology assessment
Humans
Internal Medicine
Mastectomy - methods
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Staging
Nitriles - administration & dosage
Nitriles - adverse effects
Oncology
Part 1
Pharmacology/Toxicology
Randomized Controlled Trials as Topic
Rheumatology
Risk Assessment
Survival Analysis
Tamoxifen - administration & dosage
Tamoxifen - adverse effects
Time Factors
Treatment Outcome
Triazoles - administration & dosage
Triazoles - adverse effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and overall survival. More recently, aromatase inhibitors (AI) have been tested in several randomized clinical trials in this setting. The studies have tested either AI versus TAM or different sequential approaches combining the two agents. While the most effective strategy remains to be determined, overall, incorporation of AI resulted in better disease-free survival, particularly in the worst-prognosis subgroup of patients. In addition, long-term treatment with AI was, in general, well tolerated. However, mature results are needed in order to be able to assess the effect in overall survival. The authors of this supplement paper include the key points of roundtable presentations and discussions of hormonal therapy in breast cancer by topic.
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-011-0017-1